In non-glioma settings, MUC1-C has been associated with metabolic reprogramming in esophageal squamous cell carcinoma (ESCC) via the inhibition of the AKT pathway, making MUC-1 a potential target for treating ESCC [70]. This evidence concerns the gene AKT1 and esophageal squamous cell carcinoma.